Abstract 1730P
Background
Lung cancer remains the leading cause of cancer incidence and mortality worldwide. Smoking habit has been regarded as the most important risk factor for lung cancer and therefore smoking control is considered the most effective method of prevention. Nevertheless, genetic susceptibility may also affect lung cancer risk.
Methods
Technische Informationsbibliothek (TIB) in Germany have merged data from Electronic Health Records (EHR) and database from Hospital Universitario Puerta de Hierro (HUPHM) and the Thoracic Tumors Registry (TTR) from the Spanish Lung Cancer Group (SLCG). We have used Jaccard Index (JI), a statistic tool used for gauging the similarity and diversity of sample sets. JI measures normalized co-occurrence between sample sets (e.g., patients with cancer family history and patients with biomarkers); it corresponds to the size of the intersection divided by the size of the union of the sets.
Results
15.337 patients were enrolled. 4.525 patients had unknown family history of cancer and were excluded; 5.110 reported not cancer family history. Of the other 5.702 patients, 919 had a prior cancer history and 4.749 did not; 35 patients had unknown cancer history. Lung cancer is the cancer that co-occurs more frequently in fathers and brothers of patients with lung cancer. Most of the patients with lung cancer who have relatives with other types of cancer (rather than lung cancer) are older than 50. Gender does not have a strong effect on co-occurrence of having cancer family history. Biomarkers like EGFR, ALK, ROS1, KRAS, BRAF, MET, and PD-L1 are seen mostly in the patients who have a father or at least one brother with lung cancer, or patients with no relative or at least one relative with other types of cancers. Most of the patients with biomarkers HER2, FGFR1, or RET and with mother with lung cancer are seen as passive smokers rather than former smoker.
Conclusions
Patients with a family history of cancer were diagnosed at a younger age. Gender does not have a strong effect on co-occurrence of having family history of cancer. First degree family history of cancer may increase the risk of lung cancer. These findings can lead us to design specific follow-up programs in families with these characteristics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CLARIFY Project Consortium.
Funding
This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.
Disclosure
All authors have declared no conflicts of interest.